Overview of Reteplase, A Novel Thrombolytic Agent in Indian Context
نویسندگان
چکیده
Cardiovascular disorders are the major cause of concern in India with estimated mortality reaching approximately 64 million by 2015. Though two major treatment options i.e. primary angioplasty (PAMI) and intravenous thrombolysis are available for the management of ST elevation myocardial infarction (STEMI), primary angioplasty is not feasible for majority of STEMI patients in India, hence early reperfusion therapy is critical for rapidly restoring coronary blood flow and limit further myocardial necrosis in these patients. Early/prehospital administration of thrombolytic agent results in better outcome in STEMI. Reteplase, a third generation thrombolytic, because of the possibility of bolus administration provides this opportunity. In this review article, important clinical aspects regarding use of reteplase in the treatment of STEMI are summarized.
منابع مشابه
[Thrombolytic therapy of acute pulmonary embolism].
Thrombolytic therapy accelerates the dissolution of acute pulmonary embolism and is potentially lifesaving. The goal of this article is to offer a critical analysis of the use of thrombolytic therapy in this setting. Guidelines have been written and modified and new ones have been published over the past several years. Although an evidence base exists, unanswered questions remain. Despite the p...
متن کاملThe ideal fibrinolytic: can drug design improve clinical results?
Thrombolytic therapy has been a major milestone in the management of acute myocardial infarction. By restoring patency in the infarct-related vessel, early administration of thrombolytic therapy reduces the extent of myocardial damage, lowers the risk of morbidity, and prolongs survival. Importantly, however, the available thrombolytic agents have several limitations that may result in less tha...
متن کاملHistory of Thrombolytic Agents
Thrombolytics recanalize thrombotic occlusion associated with STsegment elevation myocardial infarction (STEMI) and restoration of coronary flow reduces infarct size and improves myocardial function and survival over the short-term and long-term. Thrombolytic therapy for acute myocardial infarction (AMI) was incorporated into the armamentarium of clinicians over 2 decades ago, and has evolved f...
متن کاملDetermination of Biological Activity of Recombinant Reteplase Using Clot Lysis Time and Activated Partial Thromboplastin Time (APTT) Lysis Methods: A Comparative Study
Recombinant plasminogen activator (reteplase) is a third generation thrombolytic agent which has been used on coronary artery thrombosis and acute myocardial infarction. Clot lysis assay is usually considered as a unique method to evaluate biological activity of reteplase. In this study biological activity of reteplase was determined by APTT (activated partial thromboplastin time) lysis method....
متن کاملJournal of Pharma and Pharmaceutical Sciences A Review of the Short-term Outcomes of Thrombolytics and Percutaneous Coronary Intervention in the Treatment of ST-segment Elevation Myocardial Infarction
Coronary heart disease is the single largest cause of mortality in the UK with acute myocardial infarction (AMI) being responsible for the greatest amount of deaths. Improving perfusion to the myocardium to prevent further damage or death of the cardiac tissue is the aim of treating AMI. In the UK reperfusion is achieved either through the use of an thrombolytic agent (streptokinase, alteplase,...
متن کامل